Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Jun. 30, 2021
Current assets:    
Cash $ 522,057 $ 1,041,899
Accounts receivable (net of allowance of $0 and $0, respectively) 85,113 109,589
Inventory 291,789 387,736
Other current asset 155,771 33,480
Total current assets 1,054,730 1,572,704
Total assets 1,054,730 1,572,704
Current liabilities:    
Accounts payable 180,739 459,703
Accrued expense - related party 3,000 3,000
Convertible notes payable - net of discounts 159,580  
Total current liabilities 343,319 462,703
Commitments and contingencies
Stockholders’ deficit:    
Series A Stock, ($0.001 par value, 1,000,000 shares authorized, and 1,000 issued and outstanding as of March 31, 2022 and June 30, 2021, respectively) 1 1
Series B Stock, ($0.001 par value, 5,000 shares authorized, and 3,835 and 4,665 issued and outstanding as of March 31, 2022 and June 30, 2021, respectively) 3 5
Common stock, ($0.001 par value, 200,000,000 shares authorized, and 90,931,158 issued and outstanding as of March 31, 2022 and 80,707,467 issued and outstanding as of June 30, 2021, respectively) 90,932 80,707
Additional paid in capital 28,224,365 26,226,159
Accumulated deficit (27,603,890) (25,196,871)
Total Stockholders’ Equity 711,411 1,110,001
Total Liabilities and Stockholders’ Equity $ 1,054,730 $ 1,572,704